CN Patent

CN111592524B — 恩西德尼的制备方法

Assigned to Wenzhou Tianju Wanxun Information Technology Co ltd · Expires 2023-11-17 · 2y expired

What this patent protects

本发明揭示了一种恩西德尼(Enasidenib)的制备方法，其步骤包括：6‑(6‑三氟甲基‑2‑基)‑1,3,5‑三嗪‑2,4‑二酮依次与1‑氨基‑2‑甲基‑2‑丙醇和2‑三氟甲基‑4‑氨基吡啶发生缩合反应生成目标化合物恩西德尼(I)。该制备方法工艺简洁，条件温和，安全环保，为工业化生产提供了一条新途径。

USPTO Abstract

本发明揭示了一种恩西德尼(Enasidenib)的制备方法，其步骤包括：6‑(6‑三氟甲基‑2‑基)‑1,3,5‑三嗪‑2,4‑二酮依次与1‑氨基‑2‑甲基‑2‑丙醇和2‑三氟甲基‑4‑氨基吡啶发生缩合反应生成目标化合物恩西德尼(I)。该制备方法工艺简洁，条件温和，安全环保，为工业化生产提供了一条新途径。

Drugs covered by this patent

Patent Metadata

Patent number
CN111592524B
Jurisdiction
CN
Classification
—
Expires
2023-11-17
Drug substance claim
No
Drug product claim
No
Assignee
Wenzhou Tianju Wanxun Information Technology Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.